Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

P Cottu , V d'Hondt (1) , S Dureau , F Lerebours , I Desmoulins , Pe Heudel , Fp Duhoux , C Levy , Ma Mouret-Reynier (2, 3) , F Dalenc , Js Frenel , C Jouannaud , L Venat-Bouvet , S. Nguyen , Jm Ferrero , Jl Canon , Grenier J , C. Callens (4) , D Gentien , J Lemonnier , A Vincent-Salomon , S Delaloge

1 IRCM - U1194 Inserm - UM - Institut de Recherche en Cancérologie de Montpellier
2 IMoST - Imagerie Moléculaire et Stratégies Théranostiques
3 UNICANCER/CJP - Centre Jean Perrin [Clermont-Ferrand]
4 UMR CNRS 8179

Palbociclib is a CDK4/6 inhibitor with demonstrated efficacy and safety in combination with endocrine therapy in advanced luminal breast cancer (LBC). We evaluated the respective efficacy and safety of chemotherapy and letrozole-palbociclib (LETPAL) combination as neoadjuvant treatment in patients with high-risk LBC.

Domaines: Cancer

P Cottu, V d'Hondt, S Dureau, F Lerebours, I Desmoulins, et al.. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Annals of Oncology, 2018, ⟨10.1093/annonc/mdy448⟩. ⟨hal-01934672⟩